147 related articles for article (PubMed ID: 23162643)
1. Nedaplatin and irinotecan combination therapy is equally effective and less toxic than cisplatin and irinotecan for patients with primary clear cell adenocarcinoma of the ovary and recurrent ovarian carcinoma.
Machida S; Sato T; Fujiwara H; Saga Y; Takei Y; Taneichi A; Nonaka H; Suzuki M
Oncol Lett; 2012 Nov; 4(5):1017-1022. PubMed ID: 23162643
[TBL] [Abstract][Full Text] [Related]
2. [Combination of irinotecan hydrochloride (CPT-11) and cisplatin as a new regimen for patients with advanced ovarian cancer].
Sugiyama T; Nishida T; Kataoka A; Imaishi K; Komai K; Ushijima K; Hasuo Y; Ookura N; Yakushiji M
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Sep; 48(9):827-34. PubMed ID: 8841050
[TBL] [Abstract][Full Text] [Related]
3. Combination of irinotecan (CPT-11) and nedaplatin (NDP) for recurrent patients with uterine cervical cancer.
Ohara T; Kobayashi Y; Yoshida A; Yoshioka N; Yahagi N; Kondo H; Tozawa A; Kiguchi K; Suzuki N
Int J Clin Oncol; 2013 Dec; 18(6):1102-6. PubMed ID: 23095879
[TBL] [Abstract][Full Text] [Related]
4. Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
Ichikawa R; Torii Y; Oe S; Kawamura K; Kato R; Hasegawa K; Udagawa Y
Arch Gynecol Obstet; 2014 Nov; 290(5):979-84. PubMed ID: 24798935
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study.
Takakura S; Takano M; Takahashi F; Saito T; Aoki D; Inaba N; Noda K; Sugiyama T; Ochiai K;
Int J Gynecol Cancer; 2010 Feb; 20(2):240-7. PubMed ID: 20169667
[TBL] [Abstract][Full Text] [Related]
6. [Phase II multicenter clinical trial of nedaplatin in the treatment of malignant tumors].
Zhang P; Feng FY; Wu LY; Hu Y; Liu JW; Gao YJ; Guan XQ; Nan KJ; Suo AL; Wang XW; Zhang MH; Zhang WD; Li CW; Zhang Y; Zhao JB
Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):230-4. PubMed ID: 16875614
[TBL] [Abstract][Full Text] [Related]
7. Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial.
Sugiyama T; Okamoto A; Enomoto T; Hamano T; Aotani E; Terao Y; Suzuki N; Mikami M; Yaegashi N; Kato K; Yoshikawa H; Yokoyama Y; Tanabe H; Nishino K; Nomura H; Kim JW; Kim BG; Pignata S; Alexandre J; Green J; Isonishi S; Terauchi F; Fujiwara K; Aoki D
J Clin Oncol; 2016 Aug; 34(24):2881-7. PubMed ID: 27400948
[TBL] [Abstract][Full Text] [Related]
8. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
Nishikawa K; Fujitani K; Inagaki H; Akamaru Y; Tokunaga S; Takagi M; Tamura S; Sugimoto N; Shigematsu T; Yoshikawa T; Ishiguro T; Nakamura M; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J; Tsujinaka T
Eur J Cancer; 2015 May; 51(7):808-16. PubMed ID: 25797356
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of combination chemotherapy using irinotecan and nedaplatin for patients with recurrent and refractory endometrial carcinomas: preliminary analysis and literature review.
Miyamoto M; Takano M; Kuwahara M; Soyama H; Kato K; Matuura H; Sakamoto T; Takasaki K; Aoyama T; Yoshikawa T; Furuya K
Cancer Chemother Pharmacol; 2018 Jan; 81(1):111-117. PubMed ID: 29124328
[TBL] [Abstract][Full Text] [Related]
10. In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction.
Kanzawa F; Koizumi F; Koh Y; Nakamura T; Tatsumi Y; Fukumoto H; Saijo N; Yoshioka T; Nishio K
Clin Cancer Res; 2001 Jan; 7(1):202-9. PubMed ID: 11205910
[TBL] [Abstract][Full Text] [Related]
11. Phase II clinical study of neoadjuvant chemotherapy with CDDP/CPT-11 regimen in combination with radical hysterectomy for cervical cancer with a bulky mass.
Shoji T; Takatori E; Furutake Y; Takada A; Nagasawa T; Omi H; Kagabu M; Honda T; Miura F; Takeuchi S; Kumagai S; Yoshizaki A; Sato A; Sugiyama T
Int J Clin Oncol; 2016 Dec; 21(6):1120-1127. PubMed ID: 27342833
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for cervical squamous cell carcinoma: Japanese gynecologic oncology group study.
Yamamoto K; Kokawa K; Umesaki N; Nishimura R; Hasegawa K; Konishi I; Saji F; Nishida M; Noguchi H; Takizawa K
Oncol Rep; 2009 Apr; 21(4):1005-9. PubMed ID: 19288001
[TBL] [Abstract][Full Text] [Related]
13. Comparison between nedaplatin and cisplatin plus docetaxel combined with intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma: a multicenter randomized phase II clinical trial.
Tang C; Wu F; Wang R; Lu H; Li G; Liu M; Zhu H; Zhu J; Zhang Y; Hu K
Am J Cancer Res; 2016; 6(9):2064-2075. PubMed ID: 27725911
[TBL] [Abstract][Full Text] [Related]
14. Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis.
Takano M; Sugiyama T; Yaegashi N; Suzuki M; Tsuda H; Sagae S; Udagawa Y; Kuzuya K; Kigawa J; Takeuchi S; Tsuda H; Moriya T; Kikuchi Y
Int J Clin Oncol; 2007 Aug; 12(4):256-60. PubMed ID: 17701003
[TBL] [Abstract][Full Text] [Related]
15. A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
Kakolyris S; Souglakos J; Agelaki S; Kourousis CH; Mavroudis D; Sarra E; Malliotakis P; Georgoulias V
Lung Cancer; 2000 Dec; 30(3):193-8. PubMed ID: 11137204
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study).
Shoji T; Takatori E; Omi H; Kagabu M; Honda T; Futagami M; Yokoyama Y; Kaiho M; Tokunaga H; Otsuki T; Takano T; Yaegashi N; Kojimahara T; Ohta T; Nagase S; Soeda S; Watanebe T; Nishiyama H; Sugiyama T
Cancer Chemother Pharmacol; 2017 Aug; 80(2):355-361. PubMed ID: 28656383
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of combination chemotherapy using irinotecan hydrochloride and nedaplatin for advanced or recurrent cervical cancer.
Machida S; Ohwada M; Fujiwara H; Konno R; Takano M; Kita T; Kikuchi Y; Komiyama S; Mikami M; Suzuki M
Oncology; 2003; 65(2):102-7. PubMed ID: 12931014
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
Oshita F; Yamada K; Kato Y; Ikehara M; Noda K; Tanaka G; Nomura I; Suzuki R; Saito H
Cancer Chemother Pharmacol; 2003 Jul; 52(1):73-8. PubMed ID: 12750839
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of low-dose CDDP and CPT-11 for patients with intestinal type of gastric adenocarcinoma].
Nagahori Y; Nagahori K; Hamaguchi Y; Fukushima T; Masui H; Mogaki M; Abe T
Gan To Kagaku Ryoho; 2008 Sep; 35(9):1555-9. PubMed ID: 18799911
[TBL] [Abstract][Full Text] [Related]
20. Radiation therapy combined with cis-diammine-glycolatoplatinum (nedaplatin) and 5-fluorouracil for Japanese stage II-IV esophageal cancer compared with cisplatin plus 5-fluorouracil regimen: a retrospective study.
Yamashita H; Nakagawa K; Tago M; Igaki H; Nakamura N; Shiraishi K; Sasano N; Ohtomo K
Dis Esophagus; 2006; 19(1):15-9. PubMed ID: 16364038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
